Opicapone in Parkinson’s Patients with Probable REM Sleep Behavior Disorder: Insights from the OASIS Trial
Objective: To evaluate opicapone’s effect on sleep disturbances, motor and non-motor symptoms and quality of life in Parkinson's disease (PD) patients with and without probable…Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden
Objective: To identify biological mechanisms that mediate Exenatide's effect in the brain of patients with early Parkinson’s disease(PD). Background: Tracking PD progression remains a major challenge due to…Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)
Objective: To optimize screening for subjects with dopamine transporter (DaT) imaging deficit being at high risk for prodromal Parkinson's disease (PD). Background: Efficient screening methods…Efficacy and Safety of Different Apomorphine Formulations for OFF Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the efficacy and safety of different apomorphine formulations for managing OFF episodes in Parkinson’s disease (PD) through a systematic review and meta-analysis.…Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings
Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…Characterizing the Neural Signature of Parkinsonian Freezing of Gait During an Immersive Virtual Reality Paradigm
Objective: To characterize the neural signature of Freezing of gait (FOG) in Parkinson’s disease (PD) across multiple types of triggers. Background: FOG is among the…Identifying the Prognostic Outcomes of Parkinson’s Patients with Impaired Swallow.
Objective: To identify the prognostic outcomes of patients with Parkinson’s disease (PD) when they are unable to take their oral medication and are medicated via…Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials
Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity
Objective: To verify demographic characteristics of patients with Parkinson’s disease (PD) completing a two-week inpatient multimodal intensive neurorehabilitation and care (iMINC) program and whether iMINC…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 436
- Next Page »